Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06876142 | Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory… | Phase 1 / Phase 2 | suspended | Mar 14, 2025 | National Cancer Institute (NCI) | Administrative hold pending non-safety related changes to the study design. | Safety / toxicity |
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based… | Phase 1 / Phase 2 | terminated | Sep 26, 2023 | Hoffmann-La Roche | The study was terminated prematurely because the Sponsor decided not to pursue the development of… | Sponsor / business decision |
| NCT06179888 | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple… | Phase 2 | suspended | Dec 22, 2023 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT05288062 | Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a… | Phase 2 | terminated | Mar 18, 2022 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT05874193 | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma(COSTA) | Phase 2 | withdrawn | May 24, 2023 | Cristiana Costa Chase, DO | Due to barriers in anticipated accrual | Enrollment / accrual |
| NCT05861050 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients… | Phase 1 / Phase 2 | suspended | May 16, 2023 | City of Hope Medical Center | Safety Issues | Safety / toxicity |
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | Phase 1 / Phase 2 | terminated | Sep 20, 2013 | Jennifer Amengual | Lack of funding and recruitment complications caused by COVID-19 | COVID-19 / pandemic |
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | Phase 1 | withdrawn | Dec 22, 2025 | Baylor College of Medicine | The study was revised into two separate protocols to separate treatments. We will submit as… | Other (stated, no rule matched) |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple… | Phase 1 / Phase 2 | terminated | Dec 2, 2020 | Otsuka Pharmaceutical Co., Ltd. | This is because the decision was made to conclude the trial at Phase I and not proceed to Phase II. | Other (stated, no rule matched) |
| NCT04579523 | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and… | Phase 1 | withdrawn | Oct 8, 2020 | Fred Hutchinson Cancer Center | Study withdrawn before opening to accrual. | Enrollment / accrual |
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in… | Phase 1 / Phase 2 | suspended | Aug 1, 2025 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT06572605 | External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of… | Phase 1 / Phase 2 | suspended | Aug 27, 2024 | City of Hope Medical Center | pending amendment | Other (stated, no rule matched) |
| NCT06232044 | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With… | Phase 1 / Phase 2 | suspended | Jan 30, 2024 | Alliance for Clinical Trials in Oncology | Enrollment to Dose Level 1 cohort has been met | Enrollment / accrual |
| NCT07102212 | Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding…(FOCUS) | N/A | suspended | Aug 3, 2025 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT06691685 | A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating… | Early Phase 1 | suspended | Nov 15, 2024 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | The collaborator EsoBiotec was acquired by AstraZeneca. | Other (stated, no rule matched) |
| NCT05660395 | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in… | Phase 1 | terminated | Dec 21, 2022 | ADC Therapeutics S.A. | This decision to close the study was made following interactions with regulatory authorities and in… | Safety / toxicity |
| NCT02967276 | Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma(METDEXA-MM) | Phase 2 | terminated | Nov 18, 2016 | University of Campinas, Brazil | Recruitment difficulties due to more attractive competing studies. | Enrollment / accrual |
| NCT06028373 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | Phase 1 | terminated | Sep 8, 2023 | Antengene Biologics Limited | The study was terminated because of sponsor's development strategy change | Sponsor / business decision |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Phase 1 | terminated | Apr 25, 2023 | BeOne Medicines | This decision is due to a company business decision with strategy change on the BGB-21447… | Safety / toxicity |
| NCT05199311 | Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple… | Phase 1 / Phase 2 | suspended | Jan 20, 2022 | Hackensack Meridian Health | Temporary Hold Pending Amendment Approval | Other (stated, no rule matched) |
| NCT04318327 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | Phase 1 | terminated | Mar 23, 2020 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT04855136 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma(KarMMa-7) | Phase 1 | terminated | Apr 22, 2021 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT06922604 | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System… | Phase 1 | suspended | Apr 10, 2025 | City of Hope Medical Center | Pending Amendment Approval | Other (stated, no rule matched) |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse…(EPCORE DLBCL-3) | Phase 2 | terminated | Dec 21, 2022 | Genmab | The study was terminated because sufficient data had been collected to meet the objectives of the… | Safety / toxicity |
| NCT03710421 | CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory… | Phase 1 | suspended | Oct 18, 2018 | City of Hope Medical Center | Slow/Low Accrual | Enrollment / accrual |
| NCT07045727 | Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and… | N/A | terminated | Jul 1, 2025 | Mayo Clinic | Limited funding, slow accrual | Enrollment / accrual |
| NCT07428369 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly…(LINKER-MM8) | Phase 2 / Phase 3 | withdrawn | Feb 23, 2026 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT05498545 | Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple… | Phase 1 | terminated | Aug 12, 2022 | Second Affiliated Hospital of Xi'an Jiaotong University | Achieved the proof of concept | Other (stated, no rule matched) |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | Phase 2 | terminated | Jul 12, 2022 | University of Washington | The trial closed early due to slow accrual. | Enrollment / accrual |
| NCT07340853 | CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma | Phase 1 | suspended | Jan 14, 2026 | Thomas Martin, MD | Safety Review | Safety / toxicity |
| NCT05025423 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With… | Phase 2 | terminated | Aug 27, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study sponsor withdrew funding early, forcing this study to stop all activity and close… | Funding |
| NCT06348147 | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell… | Phase 2 | withdrawn | Apr 4, 2024 | UNC Lineberger Comprehensive Cancer Center | budget | Funding |
| NCT05824689 | Fluoroquinolone Resistance Prevalence Study(FRE) | — | terminated | Apr 21, 2023 | Hackensack Meridian Health | Discontinued Recruitment | Enrollment / accrual |
| NCT03946332 | Physical Activity for Myeloma Autograft Longitudinal Study(PAMAL) | N/A | terminated | May 10, 2019 | Centre Hospitalier Universitaire, Amiens | The study has stopped after the investigator's decision. The latter desires to analyse the… | Investigator |
| NCT07195617 | Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in…(r/r MM) | N/A | withdrawn | Sep 26, 2025 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT01421927 | Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed…(REVALLO) | Phase 1 | terminated | Aug 23, 2011 | University Hospital, Bordeaux | target number of inclusion not reached | Other (stated, no rule matched) |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | Phase 1 / Phase 2 | terminated | Apr 1, 2021 | Genmab | The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review… | Sponsor / business decision |
| NCT07082270 | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory… | Phase 1 | withdrawn | Jul 24, 2025 | Roswell Park Cancer Institute | Sponsor withdrawal of supplying investigational drug | Other (stated, no rule matched) |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT03757221 | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory…(IDARA) | Phase 2 | terminated | Nov 28, 2018 | University Hospital, Caen | Early termination (regarding the follow-up of the patients). The required sample size was reached,… | Other (stated, no rule matched) |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT06698744 | UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | withdrawn | Nov 21, 2024 | David Wald | Replaced by study by different sponsor | Other (stated, no rule matched) |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT06663046 | Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma | Early Phase 1 | suspended | Oct 29, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT05050461 | Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin…(LYMPHO-CoVac) | N/A | terminated | Sep 20, 2021 | Versailles Hospital | Given the evolution of Covid 19, patient inclusions became very difficult or even non-existent in… | COVID-19 / pandemic |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And…(MAPtivate-6) | Phase 1 / Phase 2 | terminated | Jun 9, 2023 | Pfizer | Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not… | Safety / toxicity |
| NCT03506373 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory… | Phase 2 | terminated | Apr 24, 2018 | Mayo Clinic | Discontinued after interim analysis for futility; no treatment successes observed in the first 12… | Efficacy / futility |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD)… | Phase 4 | terminated | Jun 1, 2017 | Takeda | All participants on the study have concluded treatment, core study activities are complete, and the… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 6 hours agoSource updated Sep 30, 2026source: clinicaltrials